Cognitive Behavioral Therapy (CBT), Modafinil, or Both for MS Fatigue
Many individuals with MS suffer from fatigue, which can be their most disabling symptom. Research is needed to figure out how to match treatments to individual patients so that the treatments will have the greatest effect.
The purpose of this clinical trial is to compare the effectiveness of 3 treatments for fatigue in MS: 1) a commonly used behavioral treatment strategy (telephone-based cognitive behavioral therapy (CBT), 2) a commonly used medication (modafinil), and 3) a combination of both therapies. Each participant will receive one of these 3 treatments for a total of 12 weeks.
Throughout the trial, participants will be given several short surveys (online or in person) to assess fatigue, sleep, and other symptoms. Before and after treatment, participants will wear a watch-like device for 7 days to measure symptoms as well as sleep and physical activity.
This study is funded by the Patient-Centered Outcomes Research Institute (PCORI).
Learn more about the COMBO-MS study and other clinical trials online.
Recently, a manuscript discussing the design of the COMBO-MS study was published in Contemporary Clinical Trials.
Recruitment for the COMBO study is now complete. The COMBO study is closed for enrollment of new participants. If you have other questions about the study, please email us at comboms@uw.edu.
